ArticleJournal of hepato-biliary-pancreatic sciences2026
Tumor Cell Count and Total Cell Count as Surrogate Indicators of Comprehensive Genomic Profiling Success in Pancreatic Cancer Specimens Collected by Endoscopic Ultrasonography-Guided Tissue Acquisition.
Article in Journal of hepato-biliary-pancreatic sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesWe aimed to establish the tumor cell count and total cell count as surrogate criteria on the basis of the tissue area of biopsy specimen by endoscopic ultrasound-guided tissue acquisition (EUS-TA) for comprehensive genomic profiling (CGP) in pancreatic cancer.
methodsSamples from 114 patients with unresectable pancreatic ductal adenocarcinoma were analyzed. Tumor cells were visually counted, and total cells were quantified with imaging software. Receiver operating characteristic curves determined optimal cutoffs for achieving DNA yield ≥ 200 ng using the OncoGuide NCC Oncopanel.
resultsThresholds of 2300 tumor cells (AUC 0.653, 95% CI 0.552-0.750) and 5923 total cells (AUC 0.671, 95% CI 0.565-0.778) were identified. For ≥ 2300 tumor cells, sensitivity was 48.7% and specificity 91.2%, with a positive predictive value (PPV) of 92.9%. For ≥ 5923 total cells, sensitivity was 52.5% and specificity 82.4%, with a PPV of 87.5%. A clinically practical threshold of 6000 total cells yielded a sensitivity of 48.8%, a specificity of 82.4%, and a PPV of 86.7%.
conclusionTumor cell counts ≥ 2300 and total cell counts ≥ 6000 may serve as surrogate criteria for tissue area to determine EUS-TA specimen suitability for CGP in pancreatic cancer. Given that tumor cell count is a more biologically relevant indicator, total cell count should be used as a supplementary indicator.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.